• Daniel J Berlau, María M Corrada, John L Robinson, Felix Geser, Steven E Arnold, Virginia M-Y Lee, Claudia H Kawas, and John Q Trojanowski.
• Department of Pharmaceutical Sciences, School of Pharmacy, Regis University, Denver, CO, USA. Electronic address: dberlau@regis.edu.
• Alzheimers Dement. 2013 Nov 1; 9 (6): 699-705.

ObjectiveApolipoprotein E (APOE) ε2 carriers may be protected from dementia because of reduced levels of cortical β-amyloid. In the oldest-old, however, APOE ε2 carriers have high β-amyloid plaque scores and preserved cognition. We compared different measures of β-amyloid pathology across APOE genotypes in the oldest-old, and their relationship with dementia.MethodsThe study included 96 participants from The 90+ Study. Using all information, dementia diagnoses were made. Neuropathological examination included staging for amyloid plaques and β-amyloid cortical percent area stained by NAB228 antibody.ResultsBoth APOE ε2 and APOE ε4 carriers had high Consortium to Establish a Registry for Alzheimer's Disease plaque scores. However, APOE ε2 carriers had low cortical β-amyloid percent areas. β-amyloid percent area was associated with dementia across APOE genotypes.ConclusionsLower levels of percent area in APOE ε2 carriers may reflect lower total β-amyloid and may contribute to APOE ε2 carriers' decreased risk of dementia, despite high β-amyloid plaque scores. The relationship between β-amyloid plaques and dementia in the oldest-old may vary by APOE genotype.Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

29 keywords...

hide…